Loading clinical trials...
Loading clinical trials...
A Phase I, Open Label, Multiple Dose, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of Anti-BAFFR mAb(Monoclonal Antibody), ESG206 in Subjects With B-cell Lymphoid Malignancies
Conditions
Interventions
ESG206
Locations
1
China
Beijing Cancer Hospital
Beijing, China
Start Date
August 2, 2023
Primary Completion Date
January 22, 2025
Completion Date
January 22, 2025
Last Updated
September 12, 2025
Lead Sponsor
Shanghai Escugen Biotechnology Co., Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions